Cargando…

Identification of an N6-methyladenosine (m6A)-related signature associated with clinical prognosis, immune response, and chemotherapy in primary glioblastomas

BACKGROUND: N6-methyladenosine (m6A) RNA methylation regulators play crucial role in tumorigenicity and progression. However, their biological significance in primary glioblastomas (GBM) has not been fully elucidated. METHODS: In the present study, we evaluated the 22 m6A RNA regulators using the in...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Zhiqiang, Zhang, Jianbo, Liu, Ziying, Su, Jiahao, Xu, Jing, Li, Zhenjun, Meng, Hongliang, Zhang, Heng, Huang, Minjie, Zhao, Donghai, Duan, Chuanzhi, He, Xuying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8421967/
https://www.ncbi.nlm.nih.gov/pubmed/34532378
http://dx.doi.org/10.21037/atm-21-3139
_version_ 1783749188194926592
author Cai, Zhiqiang
Zhang, Jianbo
Liu, Ziying
Su, Jiahao
Xu, Jing
Li, Zhenjun
Meng, Hongliang
Zhang, Heng
Huang, Minjie
Zhao, Donghai
Duan, Chuanzhi
He, Xuying
author_facet Cai, Zhiqiang
Zhang, Jianbo
Liu, Ziying
Su, Jiahao
Xu, Jing
Li, Zhenjun
Meng, Hongliang
Zhang, Heng
Huang, Minjie
Zhao, Donghai
Duan, Chuanzhi
He, Xuying
author_sort Cai, Zhiqiang
collection PubMed
description BACKGROUND: N6-methyladenosine (m6A) RNA methylation regulators play crucial role in tumorigenicity and progression. However, their biological significance in primary glioblastomas (GBM) has not been fully elucidated. METHODS: In the present study, we evaluated the 22 m6A RNA regulators using the integrated data of primary GBM samples from The Cancer Genome Atlas and Chinese Glioma Genome Atlas databases. The different m6A modification patterns and m6A-related gene signature in primary GBM were distinguished by using principal component analysis. Single-sample gene set enrichment analysis was introduced to assess the relative level of immune infiltration. Gene set variation analysis was performed to calculate the enrichment score of the signaling pathways for different clusters. An m6A scoring scheme was established to evaluate the m6A modification pattern in individual tumors in order to predict prognosis and evaluate tumor microenvironment (TME) cell infiltration, immune response, and chemotherapy effect in primary GBM. RESULTS: Two distinct m6A modification subgroups associated with different clinical features and biological pathways were identified among the 371 primary GBM. Based on 132 prognostic m6A phenotype-related differentially expressed genes (DEGs) between 2 m6A cluster subgroups, an m6A scoring model was constructed to assess the m6A modification pattern in individual tumors. The high-m6A score group was associated with better prognosis and immune response and worse chemotherapy effect. CONCLUSIONS: The findings of the present study indicate the potential role of m6A modification in primary GBM, which will help enhance our understanding of TME characteristics, predict clinical prognosis, and provide important insight into effective immunotherapy and chemotherapy.
format Online
Article
Text
id pubmed-8421967
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-84219672021-09-15 Identification of an N6-methyladenosine (m6A)-related signature associated with clinical prognosis, immune response, and chemotherapy in primary glioblastomas Cai, Zhiqiang Zhang, Jianbo Liu, Ziying Su, Jiahao Xu, Jing Li, Zhenjun Meng, Hongliang Zhang, Heng Huang, Minjie Zhao, Donghai Duan, Chuanzhi He, Xuying Ann Transl Med Original Article BACKGROUND: N6-methyladenosine (m6A) RNA methylation regulators play crucial role in tumorigenicity and progression. However, their biological significance in primary glioblastomas (GBM) has not been fully elucidated. METHODS: In the present study, we evaluated the 22 m6A RNA regulators using the integrated data of primary GBM samples from The Cancer Genome Atlas and Chinese Glioma Genome Atlas databases. The different m6A modification patterns and m6A-related gene signature in primary GBM were distinguished by using principal component analysis. Single-sample gene set enrichment analysis was introduced to assess the relative level of immune infiltration. Gene set variation analysis was performed to calculate the enrichment score of the signaling pathways for different clusters. An m6A scoring scheme was established to evaluate the m6A modification pattern in individual tumors in order to predict prognosis and evaluate tumor microenvironment (TME) cell infiltration, immune response, and chemotherapy effect in primary GBM. RESULTS: Two distinct m6A modification subgroups associated with different clinical features and biological pathways were identified among the 371 primary GBM. Based on 132 prognostic m6A phenotype-related differentially expressed genes (DEGs) between 2 m6A cluster subgroups, an m6A scoring model was constructed to assess the m6A modification pattern in individual tumors. The high-m6A score group was associated with better prognosis and immune response and worse chemotherapy effect. CONCLUSIONS: The findings of the present study indicate the potential role of m6A modification in primary GBM, which will help enhance our understanding of TME characteristics, predict clinical prognosis, and provide important insight into effective immunotherapy and chemotherapy. AME Publishing Company 2021-08 /pmc/articles/PMC8421967/ /pubmed/34532378 http://dx.doi.org/10.21037/atm-21-3139 Text en 2021 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Cai, Zhiqiang
Zhang, Jianbo
Liu, Ziying
Su, Jiahao
Xu, Jing
Li, Zhenjun
Meng, Hongliang
Zhang, Heng
Huang, Minjie
Zhao, Donghai
Duan, Chuanzhi
He, Xuying
Identification of an N6-methyladenosine (m6A)-related signature associated with clinical prognosis, immune response, and chemotherapy in primary glioblastomas
title Identification of an N6-methyladenosine (m6A)-related signature associated with clinical prognosis, immune response, and chemotherapy in primary glioblastomas
title_full Identification of an N6-methyladenosine (m6A)-related signature associated with clinical prognosis, immune response, and chemotherapy in primary glioblastomas
title_fullStr Identification of an N6-methyladenosine (m6A)-related signature associated with clinical prognosis, immune response, and chemotherapy in primary glioblastomas
title_full_unstemmed Identification of an N6-methyladenosine (m6A)-related signature associated with clinical prognosis, immune response, and chemotherapy in primary glioblastomas
title_short Identification of an N6-methyladenosine (m6A)-related signature associated with clinical prognosis, immune response, and chemotherapy in primary glioblastomas
title_sort identification of an n6-methyladenosine (m6a)-related signature associated with clinical prognosis, immune response, and chemotherapy in primary glioblastomas
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8421967/
https://www.ncbi.nlm.nih.gov/pubmed/34532378
http://dx.doi.org/10.21037/atm-21-3139
work_keys_str_mv AT caizhiqiang identificationofann6methyladenosinem6arelatedsignatureassociatedwithclinicalprognosisimmuneresponseandchemotherapyinprimaryglioblastomas
AT zhangjianbo identificationofann6methyladenosinem6arelatedsignatureassociatedwithclinicalprognosisimmuneresponseandchemotherapyinprimaryglioblastomas
AT liuziying identificationofann6methyladenosinem6arelatedsignatureassociatedwithclinicalprognosisimmuneresponseandchemotherapyinprimaryglioblastomas
AT sujiahao identificationofann6methyladenosinem6arelatedsignatureassociatedwithclinicalprognosisimmuneresponseandchemotherapyinprimaryglioblastomas
AT xujing identificationofann6methyladenosinem6arelatedsignatureassociatedwithclinicalprognosisimmuneresponseandchemotherapyinprimaryglioblastomas
AT lizhenjun identificationofann6methyladenosinem6arelatedsignatureassociatedwithclinicalprognosisimmuneresponseandchemotherapyinprimaryglioblastomas
AT menghongliang identificationofann6methyladenosinem6arelatedsignatureassociatedwithclinicalprognosisimmuneresponseandchemotherapyinprimaryglioblastomas
AT zhangheng identificationofann6methyladenosinem6arelatedsignatureassociatedwithclinicalprognosisimmuneresponseandchemotherapyinprimaryglioblastomas
AT huangminjie identificationofann6methyladenosinem6arelatedsignatureassociatedwithclinicalprognosisimmuneresponseandchemotherapyinprimaryglioblastomas
AT zhaodonghai identificationofann6methyladenosinem6arelatedsignatureassociatedwithclinicalprognosisimmuneresponseandchemotherapyinprimaryglioblastomas
AT duanchuanzhi identificationofann6methyladenosinem6arelatedsignatureassociatedwithclinicalprognosisimmuneresponseandchemotherapyinprimaryglioblastomas
AT hexuying identificationofann6methyladenosinem6arelatedsignatureassociatedwithclinicalprognosisimmuneresponseandchemotherapyinprimaryglioblastomas